David Amsellem
Stock Analyst at Piper Sandler
(4.81)
# 80
Out of 5,128 analysts
166
Total ratings
65.91%
Success rate
24.02%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $30 → $40 | $32.40 | +23.46% | 11 | Dec 22, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $169.37 | +29.30% | 15 | Dec 10, 2025 | |
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $3.84 | +134.38% | 1 | Nov 25, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $118 → $157 | $186.91 | -16.00% | 3 | Nov 21, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $341.64 | +11.52% | 6 | Nov 14, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $6.23 | +28.41% | 2 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Neutral | $6 → $8 | $7.21 | +10.96% | 6 | Nov 7, 2025 | |
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $233.42 | +23.81% | 3 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $35.89 | +14.24% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $13.26 | -1.96% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $140.62 | +27.29% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $29.36 | +53.27% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $51.24 | +26.85% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $27.33 | -8.53% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $37.00 | +227.03% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $8.19 | +119.78% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $47.23 | -21.66% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $56.72 | +14.60% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $12.46 | -19.74% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $21.50 | -39.53% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $79.47 | -14.43% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.90 | -62.03% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $26.00 | +61.54% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $4.08 | +414.71% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $170.69 | -33.80% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $37.55 | +11.85% | 3 | Oct 16, 2023 |
Teva Pharmaceutical Industries
Dec 22, 2025
Maintains: Overweight
Price Target: $30 → $40
Current: $32.40
Upside: +23.46%
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $169.37
Upside: +29.30%
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.84
Upside: +134.38%
Biogen
Nov 21, 2025
Reiterates: Neutral
Price Target: $118 → $157
Current: $186.91
Upside: -16.00%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $341.64
Upside: +11.52%
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $6.23
Upside: +28.41%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $7.21
Upside: +10.96%
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $233.42
Upside: +23.81%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $35.89
Upside: +14.24%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $13.26
Upside: -1.96%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $140.62
Upside: +27.29%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $29.36
Upside: +53.27%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $51.24
Upside: +26.85%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $27.33
Upside: -8.53%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $37.00
Upside: +227.03%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $8.19
Upside: +119.78%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $47.23
Upside: -21.66%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $56.72
Upside: +14.60%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $12.46
Upside: -19.74%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $21.50
Upside: -39.53%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $79.47
Upside: -14.43%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.90
Upside: -62.03%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $26.00
Upside: +61.54%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $4.08
Upside: +414.71%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $170.69
Upside: -33.80%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $37.55
Upside: +11.85%